Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label dabrafenib plus trametinib in pediatric BRAF V600-mutant glioma
jRCT2080223938Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2018
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in glioma and high-grade glioma (HGG), sponsored by Novartis. Started Jun 2018; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
gliomahigh-grade glioma (HGG)
Beyond the preview
Go deeper on jRCT2080223938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223938.